KRAS G12D mutation subtype is a prognostic factor for advanced pancreatic adenocarcinoma

Clinical and Translational Gastroenterology

Volumn 7, Issue 3, 2016, Pages E157-

  Bournet, Barbara ^a,b   Muscari, Fabrice ^a   Buscail, Camille ^c   Assenat, Eric ^d   Barthet, Marc ^e   Hammel, Pascal ^f   Selves, Janick ^b,g   Guimbaud, Rosine ^a,b   Cordelier, Pierre ^b   Buscail, Louis ^a,b  

^a CHU RANGUEIL   (France)

^b CANCER RESEARCH CENTER OF TOULOUSE   (France)

^c UNIVERSITÉ DE RENNES 1   (France)

^d UNIV MONTPELLIER   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^f BEAUJON HOSPITAL   (France)

^g TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN;

ADULT; ARTICLE; CANCER PROGNOSIS; ENDOSCOPIC ULTRASONOGRAPHY; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ONCOGENE K RAS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA;

EID: 85065186191     PISSN: 2155384X     EISSN: None     Source Type: Journal    
DOI: 10.1038/ctg.2016.18     Document Type: Article

References (38)

1. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med 2014; 371: 2140 2141.
2. Hahn SA, Schmiegel WH. Recent discoveries in cancer genetics of exocrine pancreatic neoplasia. Digestion 1998; 59: 493 501.
3. Delpu Y, Hanoun N, Lulka H et al. Genetic and epigenetic alterations in pancreatic carcinogenesis. Curr Genomics 2011; 12: 15 24.
4. Forbes SA, Bindal N, Bamford S et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011; 39 (Database issue): D945 D950.
5. di Magliano MP, Logsdon CD. Roles for KRAS in pancreatic tumor development and progression. Gastroenterology 2013; 144: 1220 1229.
6. Kawesha A, Ghaneh P, Andrén-Sandberg A et al. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. Int J Cancer 2000; 89: 469 474.
7. Lee J, Jang KT, Ki CS et al. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer 2007; 109: 1561 1568.
8. Franko J, Krasinskas AM, Nikiforova MN et al. Loss of heterozygosity predicts poor survival after resection of pancreatic adenocarcinoma. J Gastrointest Surg 2008; 12: 1664 1673.
9. Salek C, Benesova L, Zavoral M et al. Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer. World J Gastroenterol 2007; 13: 3714 3720.
10. Kim ST, Lim do H, Jang KT et al. Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy. Mol Cancer Ther 2011; 10: 1993 1999.
11. Oliveira-Cunha M, Hadfield KD, Siriwardena AK et al. EGFR and KRAS mutational analysis and their correlation to survival in pancreatic and periampullary cancer. Pancreas 2012; 41: 428 434.
12. Schultz NA, Roslind A, Christensen IJ et al. Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas. Pancreas 2012; 41: 759 766.
13. Boeck S, Jung A, Laubender RP et al. KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer. J Gastroenterol 2013; 48: 544 548.
14. Shin SH, Kim SC, Hong SM et al. Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival. Pancreas 2013; 42: 216 222.
15. Ogura T, Yamao K, Hara K et al. Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer. J Gastroenterol 2013; 48: 640 646.
16. Sinn BV, Striefler JK, Rudl MA et al. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma. Pancreas 2014; 43: 578 583.
17. Ihle NT, Byers LA, Kim ES et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst 2012; 104: 228 239.
18. Izar B, Zhou H, Heist RS et al. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma. J Thorac Oncol 2014; 9: 1363 1369.
19. Bournet B, Souque A, Senesse P et al. Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with KRAS mutation assay to distinguish pancreatic cancer from pseudotumoral chronic pancreatitis. Endoscopy 2009; 41: 552 557.
20. Bournet B, Selves J, Grand D et al. Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with a KRAS mutation assay using allelic discrimination improves the diagnosis of pancreatic cancer. J Clin Gastroenterol 2015; 49: 50 56.
21. Kotoula V, Charalambous E, Biesmans B et al. Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics. PLoS One 2009; 4: e7746.
22. Didelot A, Le Corre D, Luscan A et al. Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples. Exp Mol Pathol 2012; 92: 275 280.
23. Cserepes M, Ostoros G, Lohinai Z et al. Subtype-specific KRAS mutations in advanced lung adenocarcinoma: A retrospective study of patients treated with platinum-based chemotherapy. Eur J Cancer 2014; 50: 1819 1828.
24. Roberts PJ, Stinchcombe TE. RAS mutation: should we test for it, and does it matter? J Clin Oncol 2013; 31: 1112 1121.
25. Guibert N, Ilie M, Long E et al. KRAS mutations in lung adenocarcinoma: molecular and epidemiological characteristics, methods for detection, and therapeutic strategy perspectives. Curr Mol Med 2015; 15: 418 432.
26. Sun C, Rosendahl AH, Andersson R et al. The role of phosphatidylinositol 3-kinase signaling pathways in pancreatic cancer. Pancreatology 2011; 11: 252 260.
27. Neuzillet C, Hammel P, Tijeras-Raballand A et al. Targeting the Ras-ERK pathway in pancreatic adenocarcinoma. Cancer Metastasis Rev 2013; 32: 147 162.
28. Lièvre A, Bachet JB, Le Corre D et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992 3995.
29. Kullmann F, Hartmann A, Stöhr R et al. KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy. Oncology 2011; 81: 3 8.
30. Mosolits S, Ullenhag G, Mellstedt H. Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results. Ann Oncol 2005; 16: 847 862.
31. Toubaji A, Achtar M, Provenzano M et al. Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers. Cancer Immunol Immunother 2008; 57: 1413 1420.
32. Hartley ML, Bade NA, Prins PA et al. Pancreatic cancer, treatment options, and GI-4000. Hum Vaccin Immunother 2015; 11: 931 937.
33. Bodoky G, Timcheva C, Spigel DR et al. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) vs. capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest New Drugs 2012; 30: 1216 1223.
34. Ante JR, Somer BG, Park JO et al. A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. Eur J Cancer 2014; 50: 2072 2081.
35. Montagut C, Settleman J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett 2009; 283: 125 134.
36. LoRusso PM, Krishnamurthi SS, Rinehart JJ et al. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res 2010; 16: 1924 1937.
37. Zhu Z, Golay HG, Barbie DA. Targeting pathways downstream of KRAS in lung adenocarcinoma. Pharmacogenomics 2014;15:1507 1518.
38. Guin S, Theodorescu D. The RAS-RAL axis in cancer: evidence for mutation-specific selectivity in non-small cell lung cancer. Acta Pharmacol Sin 2015; 36: 291 297.